In the US, older adolescents and young adults with cancer have benefited less from
therapeutic advances than did either younger or older patients. One factor that may explain …

Abstract In the United States, Europe, and Australia, and probably all countries of the world,
older adolescents and young adults with cancer are under‐represented in clinical trials of …

In 1996, W. Archie Bleyer made the seminal observation that adolescents, age 15 to 19
years, had not benefited from cancer therapy improvements to the same extent as children …

The last 30 years have seen significant improvements in survival rates for children and older
adults. In contrast, the 5-year survival rate among 20 to 39 year olds has been static at …

Cancer in adolescents and young adults has unique features in addition to the special
medical, physical, psychological, and social needs of patients in this age group. The …

Adolescent patients with cancer reside in a “no-man's land” between the world of pediatric
oncology and that of “adult” medical oncology. As compared to younger and older patients …

PURPOSE.: To determine whether adolescents with cancer, who in comparison to younger
patients have a higher cancer incidence and lower mortality reduction, have equal access to …

The adolescent and young adult (AYA) oncology population has seen inferior progress in
cancer survival compared with younger children and older adults over the past 25 years …

Whereas adolescents with cancer as a group used to have a better prognosis than children
with malignant disease, trends suggest that the overall survival of 15-to 19-year-olds is now …

Abstract In the United States, adolescent and young adult (AYA) patients with cancer have
the lowest clinical trial participation rate of all age groups and slower progress in survival …